Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Glaucoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Glaucoma
    TopAbstracts in Glaucoma 11/16/2009 - (DGNews)
    External Trabeculotomy Offers Fewer Complications Than Trabeculectomy for Treating Steroid-Induced Glaucoma: Presented at AAO-PAAO - (DGDispatch)
    Future of Glaucoma Management: Presented at AAO-PAAO - (DGDispatch)
    Intravitreal Bevacizumab Provides Pain Relief, Improves Surgical Results in Patients With Neovascular Glaucoma: Presented at AAO-PAAO - (DGDispatch)
    Trabecular Microbypass Stent Safe, Effective for Refractory Open-Angle Glaucoma: Presented at AAO-PAAO - (DGDispatch)

    News archive

     Recent webcasts/CME - Glaucoma
    Adjunctive Medical Therapy: New Evidence and Treatment Strategies for Glaucoma
    Enhancing Adherence with Glaucoma Therapy: Practical Strategies for Superior Outcomes

    Webcasts/CME archive

     Recent cases - Glaucoma
      Intravitreal Bevacizumab in the Treatment of Neovascular Glaucoma Secondary to Central Retinal Vein Occlusion: A Case Report
      Topiramate-Associated Acute Glaucoma in a Migraine Patient Receiving Concomitant Citalopram Therapy: A Case-Report
      Central Retinal Artery Occlusion and Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with an Overlap Syndrome: A Case Report
      Argon Laser Peripheral Iridoplasty for Plateau Iris Associated with Iridociliary Cysts: A Case Report
      Missed Case of Axenfeld-Rieger Syndrome: A Case Report

      Cases archive
        




      my personal edition > glaucoma > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Comparison of Intraocular Pressure-Lowering Effects of Latanoprost and Bimatoprost: Presented at ARVO

      By Earl R. Nichols

      FT. LAUDERDALE, FL -- May 5, 2005 -- A novel study among glaucoma patients has shown that patients may have different responses to drugs that lower intraocular pressure (IOP) when those drugs are used in opposite eyes - even when used at the same time.

      A further finding of the research, presented here May 3rd at Association for Research in Vision and Ophthalmology Annual Meeting was that the eyes do not function in tandem, but each eye may respond differently to a particular medication.

      The study involved a cohort of 83 glaucoma patients who were treated in one eye with bimatoprost 0.03% daily while in the other eye they were treated with latanoprost 0.005% daily.

      This appears to challenge the belief that both eyes respond in concert to any specific drug -- i.e., that if bimatoprost is used in one eye, the second eye would respond with a similar reduction in intraocular pressure.

      Dr. Robert Noecker, professor of ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States, led a team of researchers who evaluated IOP at baseline and again at 1 and 2 months post-treatment.

      The researchers found that after 1 month of treatment, IOP decreased by 26.4% in the latanoprost-treated eye, compared with a decrease of 31.5% from baseline in the bimatoprost-treated eye. This 1.3 mmHg difference was statistically significant (P <.001)

      The reductions in IOP after 2 months of treatment also favoured the bimatoprost eye (28.5% vs. 23.4%). This difference was also significant P <.001.

      Adverse events, especially conjunctival hyperemia, were more common in the bimatoprost-treated eyes compared to the eyes treated with latanoprost (25% vs. 15%).

      Dr. Noecker said this proves what has been suspected for some time; that patients do not respond to all drugs in the same way. For example, almost 60% of patients using bimatoprost had a positive response to therapy compared with 23% of those using latanoprost.

      A positive response was defined as a decrease in IOP of at least 20% from baseline. In fact, he added, 16% of patients responded equally well to either drug.

      While the difference in responses was small (1.3 mmHg), this could represent an important advantage. A previous well-known study of glaucoma concluded that for every 1 mmHg reduction in IOP, the risk of progressing to glaucomatous damage of the optic nerve is reduced by 10%


      [Presentation title: Evaluation of Bimatoprost 0.03% versus Latanoprost 0.005%: A Paired Comparison Study. Poster 2452/B5]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send